Drug class
Expanded allogeneic umbilical-cord-blood haematopoietic stem-cell product; investigational cell therapy
Mechanism of action
An ex-vivo expanded cord-blood cell product intended to increase the number of transplantable haematopoietic progenitor cells and support engraftment after allogeneic transplantation. The therapeutic effect is mediated by donor-derived haematopoietic reconstitution rather than a conventional drug-receptor mechanism.
General use cases
- Investigated as an alternative donor haematopoietic stem-cell source for patients requiring allogeneic transplantation who lack a suitable matched donor; no current general marketing-authorisation indication should be assigned without confirming jurisdiction-specific approval
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
